Fig. 1From: Towards pathway-centric cancer therapies via pharmacogenomic profiling analysis of ERK signalling pathwayAssociation between genomic alterations and drug sensitivity. Cells with the indicated mutations were analyzed for sensitivities to the structures of drugs AZD6244 (a), CI-1040 (b), PD-0325901 (c), or RDEA119 (d), measured as log (IC50). Each row in the heatmap represents a gene and each column represents a cell line, with mutations in red and wildtype in yellow. 445 (a), 432 (b), 469 (c) and 469 (d) cell lines covering multiple cancer types were respectively investigated for each drug. Cell lines were ranked by drug sensitivity with a range of −5.83 to 6.39 (a), −3.52 to 7.10 (b), −7.58 to 4.70 (c), and −5.31 to 6.52 (d).Back to article page